Business UpdateMay 18, 2026, 09:07 AM
Akari Therapeutics CEO to Present at A.G.P. Healthcare Showcase
AI Summary
Akari Therapeutics announced that its President and CEO, Abizer Gaslightwala, will participate in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase on May 20, 2026. During the virtual event, management will discuss the company's differentiated antibody drug conjugate (ADC) pipeline, including its proprietary PH1 RNA splicing modulator payload platform and the lead TROP2-targeting ADC program, AKTX-101. The company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by mid-2027.
Key Highlights
- Akari Therapeutics CEO Abizer Gaslightwala to participate in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase on May 20, 2026.
- Management will discuss the company’s differentiated ADC pipeline and PH1 RNA splicing modulator payload platform.
- The presentation will highlight the lead TROP2-targeting ADC program, AKTX-101.
- AKTX-101 utilizes a novel PH1 spliceosome modulator payload, demonstrating significant preclinical activity.
- IND enabling studies for AKTX-101 have been initiated.
- Akari aims to start its First-In-Human trial for AKTX-101 by mid-2027.
- The company is also developing AKTX-102, an ADC candidate targeting CEACAM5.
Price Impact
More from AKTX